Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant mFolfirinox in Locally Advanced Rectal Cancer
NCT01804790Phase 3Completed
- Sponsor
- Unicancer
- Start
- Jan 2012
- Primary completion
- Jul 2023
- Modality
- Nanoparticles, Monoclonal Antibodies, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 3 trial of oxaliplatin, irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab, folinic acid, fluorouracil in rectal cancer, sponsored by Unicancer. Started Jan 2012; status: completed.
02
Drugs
oxaliplatinirinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumabfolinic acidfluorouracil
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT01804790.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01804790.